project id: TCGA-PRAD; case submitter id: TCGA-J9-A52E; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.86; age at index: 65; days to birth: -23741; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 23741; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 323.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; days to collection: 299; initial weight: 100.0; oct embedded: false; preservation method: Unknown; sample id: 56fb9efa-0337-4608-872b-e2ef98b1d549; sample submitter id: TCGA-J9-A52E-01A; portion id: c215a4b6-9bfb-44df-a136-97f1da28083a; portion submitter id: TCGA-J9-A52E-01A-11; slide id: c51de081-6685-49e9-9752-9dc2f6ada44d; slide submitter id: TCGA-J9-A52E-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 30.0; percent stromal cells: 0.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;